Mehdi Saeedan, Y. G. Ko, Sudhir Kumar Palat Chirakkara, S. Sinha, A. Shatila
{"title":"Hypovitaminosis D Status in Newly Diagnosed Cases of MS versus Control Group","authors":"Mehdi Saeedan, Y. G. Ko, Sudhir Kumar Palat Chirakkara, S. Sinha, A. Shatila","doi":"10.4172/2376-0389.1000199","DOIUrl":null,"url":null,"abstract":"Background: Hypovitaminosis D is amongst those strongly suggested risk factors for multiple sclerosis (MS). Although the association of vitamin D deficiency with MS has been established in several studies in recent years, there are not many studies to assess and compare the degree of Hypovitaminosis D status of newly diagnosed patients with multiple sclerosis versus control group worldwide, especially in UAE. \nObjective: To compare and observe the state of Hypovitaminosis D in newly diagnosed cases of multiple sclerosis versus control group and to determine presence of any significant association. \nMethods: In this retrospective study, 30 cases of newly diagnosed multiple sclerosis were randomly selected and matched for age and sex with 30 controls. Demographics and serum vitamin D level for both groups were evaluated. Appropriate statistical analysis was performed to show any significant association. \nResults: An independent-samples t-test was conducted. There was a significant difference in Vitamin D level for MS (Mean=37.08, SD=17.63) and control group (Mean=58.103, SD=21.5323); p<0.05. \nConclusion: Findings of this study suggest: \n1. There is significant association between vitamin D deficiency and Multiple Sclerosis 2. Hypovitaminosis D may be a contributing factor in lowering the mean age of MS diagnosis. We propose early evaluation for vitamin D insufficiency in cases of MS and emphasis on restoring serum vitamin D to satisfactory levels as part of clinical management of MS. It would be worthwhile doing a large randomized trial to establish the safety and efficacy needed to promote large-scale vitamin D supplementation.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"49 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2017-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of multiple sclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2376-0389.1000199","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Hypovitaminosis D is amongst those strongly suggested risk factors for multiple sclerosis (MS). Although the association of vitamin D deficiency with MS has been established in several studies in recent years, there are not many studies to assess and compare the degree of Hypovitaminosis D status of newly diagnosed patients with multiple sclerosis versus control group worldwide, especially in UAE.
Objective: To compare and observe the state of Hypovitaminosis D in newly diagnosed cases of multiple sclerosis versus control group and to determine presence of any significant association.
Methods: In this retrospective study, 30 cases of newly diagnosed multiple sclerosis were randomly selected and matched for age and sex with 30 controls. Demographics and serum vitamin D level for both groups were evaluated. Appropriate statistical analysis was performed to show any significant association.
Results: An independent-samples t-test was conducted. There was a significant difference in Vitamin D level for MS (Mean=37.08, SD=17.63) and control group (Mean=58.103, SD=21.5323); p<0.05.
Conclusion: Findings of this study suggest:
1. There is significant association between vitamin D deficiency and Multiple Sclerosis 2. Hypovitaminosis D may be a contributing factor in lowering the mean age of MS diagnosis. We propose early evaluation for vitamin D insufficiency in cases of MS and emphasis on restoring serum vitamin D to satisfactory levels as part of clinical management of MS. It would be worthwhile doing a large randomized trial to establish the safety and efficacy needed to promote large-scale vitamin D supplementation.